Pumas-AI
Pumas-AI develops the Pumas platform, a Julia-based nonlinear mixed effects modeling suite for pharmacometrics, and provides model-informed drug development consulting to pharmaceutical, biotechnology, regulatory, and academic customers.
- Company typePrivate
- Founded2018
- HeadquartersBaltimore, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Pumas-AI does
Pumas-AI is a privately held pharmacometric software and consulting company headquartered in Dover, Delaware, founded in 2018 by Dr. Joga Gobburu and Dr. Vijay Ivaturi, both formerly faculty at the University of Maryland. The company targets pharmaceutical and biotechnology companies, regulatory agencies, healthcare providers, and academic institutions with a horizontal platform serving the model-informed drug development (MIDD) workflow across preclinical and clinical drug development.
The company's core product is the Pumas platform, a nonlinear mixed effects (NLME) modeling system built on the Julia programming language that supports population PK/PD modeling, bioequivalence analysis, non-compartmental analysis (NCA), and regulatory submission workflows. It is complemented by DeepPumas (scientific machine learning that embeds neural networks inside pharmacometric models), PumasCP (a clinical pharmacology desktop application for study and NCA workflows), and an AI Task Force comprising AskPumas (a RAG-based assistant for pharmacometricians) and PumasAide (an AI coding-agent connector linking OpenAI, Anthropic, Google, and self-hosted models to live Pumas sessions). The company complements software with a Strategic & Scientific Consulting practice providing MIDD, regulatory submission, dose translation, and bridging/extrapolation services.
Revenue is generated through enterprise subscription licensing of Pumas, DeepPumas, and PumasCP to commercial pharma and biotech customers, professional-services fees for consulting engagements, and a freemium Academic Access Program that seeds the developer ecosystem. The company claims 60+ commercial clients, 26+ successful regulatory submissions, 1,400+ scientists across 260 institutions in the academic ecosystem, and three consecutive years of GHP recognition (2024-2026). Notable named customers include Bristol-Myers Squibb, Moderna, Otsuka, Arcus Biosciences, and Relay Therapeutics. No funding rounds are disclosed in the input, suggesting organic or internally financed growth.
Pumas-AI firmographics
Firmographics- Name
- Pumas-AI
- Legal name
- PumasAI, Inc.
- Website
- https://pumas.ai
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Pumas-AI develops the Pumas platform, a Julia-based nonlinear mixed effects modeling suite for pharmacometrics, and provides model-informed drug development consulting to pharmaceutical, biotechnology, regulatory, and academic customers.
- Ownership category
- akta.pro rank
Pumas-AI industry classification
Industry- Product category
- Pharmacometrics Software
- NAICS
- Software Publishers (5132), Custom Computer Programming Services (541511), Computer Systems Design and Related Services (54151)
- SIC
- Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industry
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
Keywords
Where Pumas-AI is headquartered
LocationHeadquarters
- HQ city
- Baltimore
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Pumas-AI business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Software Licensing: Pumas software products licensed to pharmaceutical, biotechnology companies, and regulatory agencies for commercial drug development use. Includes Pumas, DeepPumas, and PumasCP products.
- Strategic & Scientific Consulting: Model-informed drug development consulting services including dose translation, bridging & extrapolation, and regulatory submission support.
- Academic Access Program: Free access to advanced modeling tools for non-commercial research and education purposes.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Annual | Academic/Non-commercial |
| Subscription | Annual | Commercial Enterprise |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Pumas-AI product offering
Product offeringCore offering
Pumas-AI builds the Pumas software platform, a nonlinear mixed effects (NLME) modeling suite built on Julia that supports population PK/PD modeling, simulation, bioequivalence analysis, and non-compartmental analysis for pharmaceutical drug development. The company supplements its software with the DeepPumas scientific machine learning suite, the AskPumas RAG-based AI assistant, the PumasAide AI coding agent connector, and Strategic & Scientific consulting services for model-informed drug development (MIDD) and regulatory submission support.
Product overview
PumasAI offers a integrated portfolio of pharmacometric software products centered on the Pumas NLME modeling platform, supplemented by AI-powered tools (AskPumas, PumasAide), specialized modules (DeepPumas for scientific machine learning, PumasCP for clinical pharmacology workflows), and strategic consulting services. The core Pumas platform handles population PK/PD modeling, simulation, bioequivalence analysis, and NCA, while DeepPumas extends capabilities with neural network embedding for personalized predictions. Pumas for Academia provides free access for non-commercial research. The AI Task Force (AskPumas and PumasAide) brings generative AI and knowledge retrieval capabilities directly into the modeling workflow.
Differentiator
Problem solved
Functional benefit
Brands
- DeepPumas: Software suite for individualizable scientific machine learning designed for the healthcare industry. Combines dynamical, statistical, and machine learning modeling to enable full utilization of domain expertise, individualization of predictions, and information hidden in complex data.
- PumasCP
- AskPumas
- PumasAide
- Pumas
Products and services
- Pumas
- DeepPumas
- PumasCP
- Pumas for Academia
- Strategic & Scientific Consulting
Quantifiable outcome
- Saves $1B+ in money and time for 60+ clients
- +3 more outcomes
Companies that use Pumas-AI
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles3 records
Pumas-AI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability8 records
Feature7 records
Pumas-AI partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- University of MarylandcoreFounding partnership with University of Maryland where co-founders Dr. Joga Gobburu and Dr. Vijay Ivaturi were faculty members. The company originated from scientific computing experts at the university.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Pumas-AI competitors and assessment
Company assessmentDirect peers
- Simulations Plus: Provides MonolixSuite, GastroPlus, and Immunetrics for PK/PD, PBPK, and QSP modeling plus regulatory science consulting. Closest direct competitor in specialized PK-PD modeling software.
- Certara: Public, end-to-end model-informed drug development platform offering Phoenix WinNonlin/NLME, consulting, and regulatory services. Most direct and larger-scale competitor to Pumas-AI in pharmacometrics and PBPK.
- Metrum Research Group: Pharmacometrics and quantitative systems pharmacology consulting firm using NONMEM, Monolix, R, and other modeling tools. Direct competitor for MIDD consulting engagements.
- Rosa & Co. Quantitative systems pharmacology (QSP) consultancy serving pharma R&D. Adjacent peer overlapping with DeepPumas/Pumas scientific ML positioning.
- NumPy/PyMC/Pyomo ecosystem (e.g., Lixoxt): Lixoft (now part of Simulations Plus) developed MonolixSuite, the most established alternative NLME modeling platform. Direct competitor for population PK/PD software licensing.
Broad incumbents
- Schrödinger: Public computational chemistry and drug discovery platform extending into predictive modeling and pharma software. Broader incumbent with overlapping computational science customers in pharma R&D.
- Genedata: Enterprise biopharma R&D informatics platform with screening, sequencing, and biologics workflows. Broader incumbent in life science software informatics; partial overlap with Pumas in pharma R&D analytics.
- Instem (SAS-related life science tools): Provider of software and services for life sciences R&D, including preclinical and clinical workflows. Broader incumbent with overlapping pharma R&D software footprint.
Others
- Julia Computing: Commercial sponsor of the Julia language and Pumas ecosystem. Enabling partner/infrastructure provider rather than competitor; closely tied to Pumas-AI's technical foundation.
Emerging players
- Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with ML. Emerging player in AI for pharma R&D; thematically comparable as a tech-forward, AI-native approach to drug development.
Market position
Strengths5 records
Weaknesses1 record
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
Pumas-AI social profiles
Digital presencePumas-AI financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pumas-AI leadership team
Management profileNumber of profiles
Profiles9 records
Pumas-AI subsidiaries and ownership
Company hierarchySubsidiaries2 records
Pumas-AI funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pumas-AI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pumas-AI
What does Pumas-AI do?
Pumas-AI builds the Pumas software platform, a nonlinear mixed effects (NLME) modeling suite built on Julia that supports population PK/PD modeling, simulation, bioequivalence analysis, and non-compartmental analysis for pharmaceutical drug development. The company supplements its software with the DeepPumas scientific machine learning suite, the AskPumas RAG-based AI assistant, the PumasAide AI coding agent connector, and Strategic & Scientific consulting services for model-informed drug development (MIDD) and regulatory submission support.
Is Pumas-AI a public or private company?
Pumas-AI is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Pumas-AI founded?
Pumas-AI was founded in 2018. It employs 11 to 50 people.
Where is Pumas-AI based?
Pumas-AI is headquartered in Baltimore, United States, in the North America region.
How does Pumas-AI make money?
Three revenue lines are on record. Software Licensing is the primary driver. The others are strategic & Scientific Consulting and academic Access Program.
Who are Pumas-AI's main competitors?
Direct peers on record are Simulations Plus, Certara, Metrum Research Group, Rosa & Co. and NumPy/PyMC/Pyomo ecosystem (e.g., Lixoxt). Broad incumbents are Schrödinger, Genedata and Instem (SAS-related life science tools). Julia Computing is listed as an others. Recursion Pharmaceuticals is listed as an emerging player.
Does Pumas-AI have an API?
No public API is recorded for Pumas-AI.
What industry is Pumas-AI in?
Pumas-AI's product category is Pharmacometrics Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 5132 and its SIC code is 7372.